Systemic Therapy for Cutaneous Melanoma

被引：16

作者：

Treisman, Jonathan ^{[1
,2
]}

Garlie, Nina ^{[2
]}

机构：

[1] Aurora St Lukes Med Ctr, Med Consultants Inc, Milwaukee, WI 53215 USA

[2] Aurora St Lukes Med Ctr, Immunotherapy Program, Milwaukee, WI 53215 USA

来源：

CLINICS IN PLASTIC SURGERY | 2010年 / 37卷 / 01期

关键词：

Melanoma; Chemotherapy; Biochemotherapy; Interferon; Interleukin-2; PHASE-II TRIAL; COOPERATIVE-ONCOLOGY-GROUP; TUMOR-INFILTRATING LYMPHOCYTES; HIGH-DOSE INTERFERON-ALPHA-2B; PROSPECTIVE RANDOMIZED-TRIAL; PLUS PEGYLATED INTERFERON-ALPHA-2B; DISSEMINATED MALIGNANT-MELANOMA; COLONY-STIMULATING FACTOR; AMERICAN-JOINT-COMMITTEE; NODE-NEGATIVE MELANOMA;

D O I：

10.1016/j.cps.2009.07.008

中图分类号：

R61 [外科手术学];

学科分类号：

摘要：

This article provides a review of the current medical management of patients with high-risk and metastatic cutaneous melanoma, including a review of the use of adjuvant interferon therapy and a discussion of adjuvant treatments under evaluation. The use of standard chemotherapeutic agents for metastatic disease is discussed, with an emphasis on developmental therapeutics using targeted agents. This discussion includes a review of the immune therapy for metastatic melanoma, including newer immunomodulatory agents and cellular therapeutics that are expected to significantly impact the care of these patients.

引用

页码：127 / +

页数：21

共 160 条

[1]

Agarwala Sanjiv S., 1996, Current Opinion in Oncology, V8, P167, DOI 10.1097/00001622-199603000-00015

[2]

Agarwala SS, 1999, CANCER, V85, P1979, DOI 10.1002/(SICI)1097-0142(19990501)85:9<1979::AID-CNCR15>3.3.CO

[3]

2-7

[4] Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673) - A trial of the eastern cooperative oncology group [J].

Agarwala, SS ;

Neuberg, D ;

Park, Y ;

Kirkwood, JM .

CANCER, 2004, 100 (08) :1692-1698

[5]

ALEXANDER M, 2008, LANCET, V372, P117

[6] Combination of transient lymphodepletion with busulfan and fludarabine and peptide vaccination in a phase I clinical trial for patients with advanced melanoma [J].

Appay, Victor ;

Voelter, Verena ;

Rufer, Nathalie ;

Reynard, Severine ;

Jandus, Camilla ;

Gasparini, Danielle ;

Lienard, Danielle ;

Speiser, Daniel E. ;

Schneider, Philippe ;

Cerottim, Jean-Charles ;

Romero, Pedro ;

Leyvraz, Serge .

JOURNAL OF IMMUNOTHERAPY, 2007, 30 (02) :240-250

[7] Adjuvant therapy of melanoma with interferon: lessons of the past decade [J].

Ascierto, Paolo A. ;

Kirkwood, John M. .

JOURNAL OF TRANSLATIONAL MEDICINE, 2008, 6 (1)

[8] High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993 [J].

Atkins, MB ;

Lotze, MT ;

Dutcher, JP ;

Fisher, RI ;

Weiss, G ;

Margolin, K ;

Abrams, J ;

Sznol, M ;

Parkinson, D ;

Hawkins, M ;

Paradise, C ;

Kunkel, L ;

Rosenberg, SA .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (07) :2105-2116

[9] Phase III Trial Comparing Concurrent Biochemotherapy With Cisplatin, Vinblastine, Dacarbazine, Interleukin-2, and Interferon Alfa-2b With Cisplatin, Vinblastine, and Dacarbazine Alone in Patients With Metastatic Malignant Melanoma (E3695): A Trial Coordinated by the Eastern Cooperative Oncology Group [J].

Atkins, Michael B. ;

Hsu, Jessie ;

Lee, Sandra ;

Cohen, Gary I. ;

Flaherty, Lawrence E. ;

Sosman, Jeffrey A. ;

Sondak, Vernon K. ;

Kirkwood, John M. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (35) :5748-5754

[10] Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma:: A phase III study [J].

Avril, MF ;

Aamdal, S ;

Grob, JJ ;

Hauschild, A ;

Mohr, P ;

Bonerandi, JJ ;

Weichenthal, M ;

Neuber, K ;

Bieber, T ;

Gilde, K ;

Porta, VG ;

Fra, J ;

Bonneterre, J ;

Saïag, P ;

Kamanabrou, D ;

Pehamberger, H ;

Sufliarsky, J ;

Larriba, JLG ;

Scherrer, A ;

Menu, Y .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (06) :1118-1125

← 1 2 3 4 5 6 7 8 9 10 →